Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that the Company has completed a directed share issue of approximately SEK 24.7 million in accordance with the intention communicated to the market through a press release yesterday, August 26th, 2021.
The board of directors of Prostatype has, based on the authorization granted by the annual general meeting on the 16th of June 2021, and as indicated in the Company’s press release yesterday, decided to carry out a directed share issue through which the Company is provided approximately SEK 24.7 million. The subscription price in the directed share issue was set to SEK 13.00 per share, which corresponds to a discount of approximately 13.6 percent against the VWAP for the last 20 trading days until and including the 25th of August 2021. The subscription price was determined by way of an accelerated book building procedure and the directed share issue was subscribed by Swedish and international investors. The Company believes that using the flexibility provided by the directed share issue is the most appropriate alternative for the Company at this time, allowing it to raise capital in a timely and cost-effective manner and to diversify the shareholder base. By establishing the subscription price in the directed share issue through an accelerated book building procedure, it is the assessment of the board of directors that the subscription price reflects the current market conditions.
The proceeds from the directed share issue are intended to finance additional distribution agreements in the EMEA, validation studies and market entries together with the Swiss company Proteomedix AG.
Through the directed share issue, the Company’s share capital will increase by SEK 114,113.46 from SEK 791,212.20 to SEK 905,325.66, and the number of shares will increase by 1,901,891 shares, from 13,186,870 shares to 15,088,761 shares. The new shares will have the same rights attached as all other existing shares in the Company and will confer a right on dividends and other shareholder rights from the date of registration of the capital increase with the Swedish Companies Registration Office. The directed share issue results in a dilution of approximately 12.5 percent of the capital and the votes for existing shareholders based on the total number of shares and votes in the Company after the directed share issue.
Sedermera Fondkommission has acted as sole bookrunner and Advokatfirman Lindahl legal advisor in the transaction. Nordic Issuing is the issuing agent.
CEO Fredrik Persson comments
“We are happy and content to have completed this capitalization and entered into the agreement with Proteomedix AG. We can now act on the synergies we see within the two companies, in order to create better conditions for the men facing the risk of being diagnosed with prostate cancer”, says Fredrik Persson, CEO of Prostatype Genomics.
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-08-2021 09:01 CET.